Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment before surgery (neoadjuvant)…
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy as first-line treatment…
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
AstraZeneca and Merck (NYSE: MRK),known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved by the U.S. Food and Drug Administration (FDA) for the…
Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in Scotland
Merck, a leading science and technology company, invests € 35 million in biosafety testing at its Glasgow and Stirling sites, Scotland. Biosafety testing is a critical step in the drug development and manufacturing process that ensures drugs are safe, efficacious,…
MinuteClinic® receives 6th consecutive Ambulatory Health Care Accreditation from The Joint Commission
CVS Health® (NYSE: CVS) today announced that MinuteClinic, the retail medical clinic located inside select CVS Pharmacy® stores in 36 states and Washington, D.C., was awarded its sixth consecutive Ambulatory Health Care Accreditation from The Joint Commission. Since 2006 — when…
Aetna provides Morehouse School of Medicine with $140,000 community investment to advance health equity in Georgia
Aetna Better Health® of Georgia, a CVS Health® company (NYSE: CVS), announced that Aetna® provided a community investment of $140,000 to the Morehouse School of Medicine. The investment will support Morehouse School of Medicine’s Health Equity for All Lives (H.E.A.L.) student-run…
CVS Health opens new Workforce Innovation and Talent Center within Goodwill of Greater Detroit
CVS Health announced the opening of its newest Workforce Innovation and Talent Center (WITC) in collaboration with Goodwill Industries of Greater Detroit, offering comprehensive skills training, job placement and community health services. The innovation hub features a mock retail store, pharmacy and other professional…
McKesson Corporation Commences Tender Offer for Any and All 3.796% Notes Due 2024
McKesson Corporation (NYSE:MCK) (the “Company”) today announced that it has commenced an offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 3.796% Notes due 2024 (the “2024 Notes”). The Tender Offer is being made pursuant…
Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer
A McKesson business dedicated to leveraging oncology real-world evidence (RWE), clinical education, and provider technology to transform the fight against cancer, presented new data at the American Society of Clinical Oncology (ASCO) Annual Meeting which showed that 74 percent of patients with triple-negative breast…
GE HealthCare Reimagining Better Health Study Identifies the Barriers to Achieving a More Human and Flexible Healthcare Experience
GE HealthCare, a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today released Reimagining Better Health, a qualitative and quantitative study that amplifies the perspectives and needs of people at the center of healthcare — patients and clinicians. The study aims…
GE HealthCare Introduces Sonic DL: A Groundbreaking, FDA-Cleared AI Deep Learning Technology for Faster MRI
GE HealthCare today announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based technology designed to dramatically accelerate image acquisition in magnetic resonance imaging (MRI). Sonic DL enables new imaging paradigms, such as high-quality cardiac MRI…
GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI
GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically…